Category - News

Developments

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...

July 13, 2023

Developments

Theratechnologies reduces R&D headcount on sales shortfall

With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...

July 12, 2023

Executive Moves

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...

July 12, 2023

Developments

Synlogic gets FDA fast track to treat phenylketonuria

The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...

July 11, 2023

Developments

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...

July 11, 2023

Developments

MAIA updates survival data from Phase 2 NSCLC trial

MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced...

July 10, 2023

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

Developments

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Vaxart (NASDAQ:VXRT) reported positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Norovirus is the leading cause of acute viral gastroenteritis in...

July 7, 2023

Developments

Revive oral Bucillamine flunks Phase 3 COVID-19 study

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV) reported that its Phase 3 clinical study evaluating the safety and efficacy of oral Bucillamine in patients with mild- to-moderate COVID-19 did not achieve statistical...

July 6, 2023

Developments

ASLAN posts positive Phase 2b results in atopic dermatitis

ASLAN Pharmaceuticals (NASDAQ:ASLN) reported positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, which is often referred to as eczema...

July 6, 2023

Category - News

Subscribe